ライフサイエンスコーパス: papilloma virus

1 es are available against rotavirus and human papilloma virus.

2 patitis B virus, hepatitis C virus and human papilloma virus.

3 mortalized with the E6 and E7 genes of human papilloma virus.

4 ds 85-115 of the E4 protein of type 75 human papilloma virus.

5 naling such as v-src, BCR/ABL, and E6 of the papilloma virus.

6 thway since ME180 is infected with the human papilloma virus.

7 l end of the E6 protein from high-risk Human Papilloma Virus.

8 ntified as an important target for the Human Papilloma Virus.

9 tegies against oncogenesis mediated by human papilloma virus.

10 reasing percentage are associated with human papilloma virus.

11 such as the vaccines for influenza and human papilloma virus.

12 us, adeno-associated virus type 2, and human papilloma virus.

13 e to elimination of foreskin harboring human papilloma virus.

14 virus 16 copies/cell, and SiHa, 1 to 2 human papilloma virus 16 copies/cell) and two negative cell li

15 viral gene content (CaSki, 200 to 600 human papilloma virus 16 copies/cell, and SiHa, 1 to 2 human p

16 HPECs are immortalized using human papilloma virus 16 E6 and/or E7 as molecular tools to in

17 including the SV40 large T antigen and human papilloma virus 16 E6-antigen.

18 Expression of the human papilloma virus 16 E7 protein (which inactivates all mem

19 ycle checkpoints (for example, E7 from human papilloma virus 16, and cyclin D1), deregulate Myc trans

20 Human papilloma virus-16 (HPV-16) associated oropharyngeal can

21 strains were produced that secrete the human papilloma virus-16 (HPV-16) E7 protein expressed in HPV-

22 with a retroviral vector encoding the human papilloma virus 18 E6 gene, which inactivates endogenous

23 T-cell chemotaxis in a model of stable human papilloma virus-18 infection.

24 Two capsid virus-like particles, human papilloma virus (55 nm, approximately 20,000 kDa) and No

25 fect of Prdx6, which was observed in a human papilloma virus 8-induced and a chemically induced tumor

26 Infection of influenza or human papilloma virus 9-mer peptide-pulsed DCs from different

27 milies and as SPCs are associated with human papilloma virus and smoking related cancers.

28 aluate temporal trends and the role of human papilloma virus and to determine the academic training a

29 therapeutic vaccine candidates against human papilloma viruses and melanoma have been developed recen

30 tion (CRT), associated with anogenital human papilloma virus, and often appears in HIV infection.

31 High-risk human papilloma viruses are known to be associated with cervic

32 ad and neck squamous cell cancer, both human papilloma virus-associated and human papilloma virus-neg

33 f renewed importance in the context of human papilloma virus-associated disease, in which young patie

34 -16 E7 for the treatment of metastatic human papilloma virus-associated epithelial cancers (NCT028583

35 ces the effect of radiation therapy in human papilloma virus-associated oropharyngeal SCC, we hypothe

36 prognosis in unselected patients with human papilloma virus-associated oropharyngeal squamous cell c

37 ces the effect of radiation therapy in human papilloma virus-associated oropharyngeal squamous cell c

38 the metallothionein 1 promoter in the bovine papilloma virus-based expression vector drove the highes

39 induces G-to-A or C-to-T mutations in human papilloma virus cervical cell lines and genital warts.

40 NBF solutions were also evaluated for human papilloma virus content using DNA ISH.

41 ed protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has an imp

42 erface is reminiscent of that seen in bovine papilloma virus E1 protein.

43 mer d(GACCGCGGTC), containing half the human papilloma virus E2 binding site, has been solved from tw

44 sette, whose expression is controlled by the papilloma virus E2 protein.

45 ranscription of the genes encoding the human papilloma virus E6 and E7 proteins and is over-expressed

46 d by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent activatio

47 Inactivation of p53, by the human papilloma virus E6 oncoprotein, does not prevent PTEN-in

48 , ubiquitinates p53 in the presence of human papilloma virus E6 protein, while Nedd-4 does not.

49 n be abrogated by the co-expression of human papilloma virus E6 protein.

50 Elimination of p53 by expression of human papilloma virus E6 resulted in an inability to down-regu

51 The human papilloma virus E6-associated protein (E6AP) functions a

52 ts tumour growth in the B16F10-OVA and human papilloma virus-E6/E7 tumour models in mice.

53 hibition in melanoma, colon cancer and human papilloma virus-E6/E7 tumour models.

54 ntly inactivated by the binding of the human papilloma virus E7 oncoprotein in cervical cancer.

55 in affects the antitumor efficacy of a human papilloma virus E7 peptide vaccine (CyaA-E7) capable of

56 or the growthpromoting activity of the human papilloma virus E7 protein.

57 mouse embryonic fibroblasts but not in human papilloma virus-E7 expressing fibroblasts.

58 The Papilloma Virus Episteme (PaVE) was initiated by NIAID i

59 he only cell type directly infected by human papilloma virus, express functional gammac and its co-re

60 Human papilloma virus has shown differential levels of prevale

61 est women for the causative agent, the human papilloma virus, has emerged as a potential screening to

62 Vaccines against rotavirus and human papilloma virus have entered clinical use.

63 cy virus, human T cell leukemia virus, human papilloma virus, hepatitis B and C viruses, herpes simpl

64 he other group 1 carcinogens including human papilloma virus, hepatitis C virus, and Helicobacter pyl

65 he other Group 1 carcinogens including human papilloma virus, hepatitis C virus, and Helicobacter pyl

66 Risk factors, including human papilloma virus, HIV, and the practice of circumcision h

67 al diseases such as hepatitis B virus, human papilloma virus, HIV, or chronic hepatitis C.

68 ve focused on its association with the human papilloma virus; however, there have also been several s

69 ogenous retrovirus (HERV-W), HHV2, and human papilloma virus (HPV) (weakest association).

70 ere collected from women with healthy, human papilloma virus (HPV) +/- cervical intraepithelial neopl

71 a peptide from the clinically-relevant human papilloma virus (HPV) 16 E7 oncoprotein induces cytotoxi

72 Identifying human papilloma virus (HPV) and human immunodeficiency virus (

73 lecular classification on the basis of human papilloma virus (HPV) and tumor protein 53 (p53) status

74 ents whose lesions tested positive for human papilloma virus (HPV) and/or who endorsed a history of c

75 High-risk types of human papilloma virus (HPV) are increasingly associated with o

76 High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in mo

77 Human papilloma virus (HPV) causes focal infections of epithel

78 performed in those with genitourinary human papilloma virus (HPV) disease versus those without.

79 d with vemurafenib for the presence of human papilloma virus (HPV) DNA and identified 13% to be posit

80 The prevalence of human papilloma virus (HPV) DNA in different histological subt

81 We assayed for the presence of human papilloma virus (HPV) DNA in serum and/or peripheral blo

82 The E6 and E7 oncoproteins of human papilloma virus (HPV) drive the majority of genital canc

83 ppressor pathways are disrupted by the human papilloma virus (HPV) E6 and E7 oncoproteins, because E6

84 es and identified protein partners for human papilloma virus (HPV) E6 proteins.

85 Loss of p16(INK4A) or the presence of human papilloma virus (HPV) E6/E7 oncogene products not only p

86 er the past decades owing to increased human papilloma virus (HPV) exposure.

87 Recently, the human papilloma virus (HPV) has been implicated in the rising

88 es (HHVs), human polyomavirus JCV, and human papilloma virus (HPV) have been implicated in brain canc

89 ical cancer has elucidated the role of human papilloma virus (HPV) in the pathogenesis of cervical ca

90 nomas (OPSCC) that are associated with human papilloma virus (HPV) infection carry a more favorable p

91 licated estrogenic exposure as well as human papilloma virus (HPV) infection in cervical carcinogenes

92 noma (HNSCC) associated with high-risk human papilloma virus (HPV) infection is a growing clinical pr

93 confirmed by a study on the effects of human papilloma virus (HPV) infection to the EC's response to

94 In a longitudinal study of human papilloma virus (HPV) infection, female adolescents aged

95 es that have seen growing burdens with human papilloma virus (HPV) infection.

96 As persistent human papilloma virus (HPV) infections are a key causative fac

97 In a third of PSC cases, presence of human papilloma virus (HPV) is found.

98 ukocyte antigen-A*02:01 presenting the human papilloma virus (HPV) peptide HPV16 E7(11-19), 4-1BBL, a

99 case-control datasets (samples either Human Papilloma Virus (HPV) positive or negative).

100 In cervical cancer cells, human papilloma virus (HPV) protein E7 binds to Rb, releasing

101 In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely mark

102 E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the dev

103 the aerodigestive tract caused by the Human Papilloma Virus (HPV) that manifests as profoundly alter

104 Specific human papilloma virus (HPV) types appear to be necessary etiol

105 ted with approximately 13 carcinogenic human papilloma virus (HPV) types in a broader group that caus

106 Despite preventive human papilloma virus (HPV) vaccination efforts, cervical canc

107 Public trust in the human papilloma virus (HPV) vaccination programme has been cha

108 Most cervical cancers are caused by human papilloma virus (HPV), and HPV circulating tumor DNA (ct

109 4 (HHV4), human herpes virus 5 (HHV5), human papilloma virus (HPV), human JC polyoma virus (JCV), hum

110 cussed include influenza, hepatitis B, human papilloma virus (HPV), human T-cell lymphotrophic virus

111 virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic virus (

112 99% of cervical cancers are caused by human papilloma virus (HPV), measurement of HPV (HPV test) was

113 DNA of human papilloma virus (HPV), the major etiological agent of ce

114 Human papilloma virus (HPV)-16 DNA was hybridized to probes th

115 We have shown that the human papilloma virus (HPV)-16 E7 gene is sufficient to induce

116 -3a differentially regulates different human papilloma virus (HPV)-16 variants that are associated wi

117 We study a patient with the human papilloma virus (HPV)-2-driven "tree-man" phenotype and

118 es such as immune-checkpoint blockade, human papilloma virus (HPV)-directed vaccines and adoptive T c

119 of normal oral epithelial cells and a human papilloma virus (HPV)-immortalized oral epithelial cell

120 In the TC-1 mouse allograft model of human papilloma virus (HPV)-induced cancer, a single administr

121 Human papilloma virus (HPV)-like particles (VLPs) have been us

122 e present a proteogenomic study of 108 human papilloma virus (HPV)-negative head and neck squamous ce

123 ds to radioresistance, particularly of Human Papilloma Virus (HPV)-negative tumors.

124 the vulva is diverse and includes both human papilloma virus (HPV)-positive and HPV-negative pathways

125 Purpose The incidence of human papilloma virus (HPV)-positive oropharyngeal cancers has

126 articularly higher among patients with human papilloma virus (HPV)-positive tumors.

127 positive patients followed closely for human papilloma virus (HPV)-related anal neoplasia after trans

128 Using 10 images of penises with human papilloma virus (HPV)-related disease, we trained a deno

129 mor induction by pathogenic strains of human papilloma virus (HPV).

130 to tobacco, alcohol and infection with human papilloma virus (HPV).

131 d transcription of oncogenes, HIV, and human papilloma virus (HPV).

132 ith solar radiation exposure, HIV, and human papilloma virus (HPV).

133 lines in which p53 was inactivated by human papilloma virus (HPV)16E6 protein or by a dominant-negat

134 tion and screening recommendations for human papilloma virus (HPV); and appropriate testing for HIV a

135 in (LAMP-1) to the cytoplasmic/nuclear human papilloma virus (HPV-16) E7 antigen, creating a chimera

136 controlling tumors induced by type 16 human papilloma virus (HPV-16).

137 rus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV; for example, HPV16 or HPV18).

138 Over the past 20 years, high-risk human papilloma-virus (HPV) infection has been established as

139 association with high-risk subtypes of human papilloma virus (HPV16 and HPV18).

140 The impact of human papilloma virus (HPV16) E7 proteins and retinoblastoma (

141 High-risk human papilloma viruses (HPVs) have been recognized as importa

142 gical role of infection with high-risk human papilloma viruses (HPVs) in cervical carcinomas is well

143 tion of PPIs that discriminate between human papilloma viruses (HPVs) with high and low oncogenic pot

144 be infected by more than 200 types of human papilloma viruses (HPVs), and persistent HPV infections

145 d to infection with high-risk types of human papilloma viruses (HPVs).

146 al. (2014) demonstrate that high-risk human papilloma viruses (hrHPVs) attenuate the magnitude of re

147 cytokine expression and the absence of human papilloma virus in aggressive tumors.

148 ytokine expression and the presence of human papilloma virus in chemoradiation-sensitive basaloid tum

149 mal viruses--e.g., simian virus 40 or bovine papilloma virus--in which the initiator protein, T antig

150 lls transfected with the E6 protein of human papilloma virus (inactivating p53).

151 tumours induced by 'high-risk' mucosal human papilloma viruses, including human cervical carcinoma an

152 n ligase E6AP (UBE3A) is implicated in human papilloma virus-induced cervical tumorigenesis and sever

153 cess bodyweight (three provinces), and human papilloma virus infection (one province).

154 DNA methylation changes in relation to human papilloma virus infection and age.

155 n the protein-protein interaction network of papilloma virus infection.

156 Cervical cancer is associated with human papilloma virus infection.

157 s typically associated with anogenital human papilloma virus infection.

158 comprising susceptibility to cutaneous human papilloma virus infections and associated nonmelanoma sk

159 types suggest that life style related human papilloma virus infections contributed to the observed f

160 , a long-term risk of severe cutaneous human papilloma virus infections persists, possibly related to

161 al-kidney-cancer-associated breakpoint and a papilloma virus integration site.

162 Sexual transmission of human papilloma virus is a leading risk factor for cervical ca

163 that loss of p53 through mutation, or human papilloma virus-mediated inhibition, prevents recruitmen

164 The incidence of human papilloma virus-mediated oropharyngeal squamous cell car

165 h human papilloma virus-associated and human papilloma virus-negative tumors.

166 The human papilloma virus oncogene 16E6 induces telomerase activit

167 ns in the pocket and by binding of the human papilloma virus oncoprotein E7.

168 ntigen of SV40 virus, by E6 protein of human papilloma virus, or by genetic deletion led to the same

169 organs or any history of herpes virus, human papilloma virus, or human immunodeficiency virus infecti

170 We selected a murine model of human papilloma virus-positive head and neck cancer based on h

171 p-regulated DEK protein levels in both human papilloma virus-positive hyperplastic murine skin and a

172 Human papilloma virus presence does not seem to be required fo

173 mental, and sexual health (including a human papilloma virus programme), an investment of US$4.6 per

174 Inactivation of pocket proteins with human papilloma virus protein E7 partially, but not completely

175 though a recent study also showed that human papilloma virus-reactive T cells can induce complete reg

176 selected for this purpose, a model of human papilloma virus-related head and neck cancer and a model

177 his purpose, we used a murine model of human papilloma virus-related head and neck cancer paired with

178 Funding for human papilloma virus-related projects gradually rose, from 3.

179 cers, a malignancy associated with oncogenic papilloma viruses, remain a major disease burden in the

180 ty against herpes simplex virus (HSV), human papilloma virus, respiratory syncytial virus (RSV), deng

181 the E6 and E7 transforming proteins of human papilloma virus serotype 16 was necessary to establish l

182 human immunodeficiency virus (HIV) and human papilloma virus; several cancers, including follicular l

183 Human papilloma virus status was not found to be associated wi

184 Peptides from papilloma virus strains containing the motif VHFFK induc

185 Despite infection with high-risk human papilloma virus subtypes, which is a major etiological f

186 These guidelines incorporate human papilloma virus testing based on a multicenter trial doc

187 ppropriate methods of incorporation of human papilloma virus testing into the screening protocols.

188 r, and MIS inhibits the growth of both human papilloma virus-transformed and non-human papilloma viru

189 an papilloma virus-transformed and non-human papilloma virus-transformed cervical cell lines, with a

190 ternary complex comprising full-length human papilloma virus type 16 (HPV-16) E6, the LxxLL motif of

191 R2 is able to induce the expression of human papilloma virus type 16 (HPV-16) genes via binding to a

192 is able to activate expression of the human papilloma virus type 16 (HPV-16) upstream regulatory reg

193 E7 is the main transforming protein of human papilloma virus type 16 (HPV16) which is implicated in t

194 Inhibition of wild-type p53, by either human papilloma virus type 16 E6 or a dominant-negative p53, r

195 ental cultures with viral oncoproteins human papilloma virus type 16 E6/E7 with and without hTERT, an

196 which binds pRB), or both E6 and E7 of human papilloma virus type 16.

197 me 8q24.21 at which integration of the human papilloma virus type 18 (HPV-18) genome occurred and tha

198 c, mutant type 5 adenovirus (Ad5), and human papilloma virus type 18.

199 A peptide from human papilloma virus type 40 (HPV 40) containing VHFFR, and o

200 A PCR screening detected human papilloma virus type 45 DNA (high-risk subtype), and foc

201 nkage of CRT to a model tumor antigen, human papilloma virus type-16 (HPV-16) E7, for the development

202 nced adjuvant activity, such as in the human papilloma virus vaccine Cervarix(R).

203 For example, the human papilloma virus vaccine requires aluminium salt adjuvant

204 or the expression of the E6 protein of human papilloma virus, were treated with exogenous ceramide, t

205 man virus in urethral swab samples was human papilloma virus, whereas the most abundant bacteriophage